Michael J Kozal MD
Professor of Medicine (AIDS); Chief Section of Infectious Diseases VA CT Healthcare System; Director Yale HIV Clinical Trials; Acting Chief, Medical Service VACHS & Vice Chair, VA Medical Service for the Yale Dept. of Internal Medicine
Departments & Organizations
Genetic determinants of HIV and Hepatitis C drug resistance; New technologies to detect low abundance drug resistant viral variants more...
- M.D., University of Nebraska, 1988
- Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St. John E, Moreno E and Kozal M. Virologic Failures on Initial boosted-PI Regimen Infrequently Possess Low-level Variants with Major PI Resistance Mutations by Ultra-deep Sequencing. PLoS One 2012;7(2):e30118. PMID: 22355307
- Li JZ, Paredes R, Ribaudo H, Svarovskaia ES, Kozal MJ, et al. Relationship between Minority NNRTI Resistance Mutations, Adherence, and the Risk of Virologic Failure. AIDS. 2012 Jan 14;26(2):185-92. PMID: 22179227
- Li JZ, Paredes R, Ribaudo H, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Minority HIV-1 Drug Resistance Mutations and the Risk of NNRTI-based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis. JAMA, 2011;305(13):1327-1335.